Goteborg

• An Open label Study of Teclistamab in Subjects with Relapsed and Refractory Multiple Myeloma Ended recruitment
  2023-503438-40-00 7 2017-10-05 Relapsed/Refractory Multiple Myeloma
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended recruitment
  2023-510298-33-00 4 2016-11-29 Prostate Cancer
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in … Ended recruitment
  2024-513521-23-00 5 2015-08-19 Prostate Cancer
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• PREDIX HER2 - preoperative treatment of HER2 positive breast cancer Ended recruitment
  2023-508411-23-00 4 2014-11-12 Primary breast cancer
• Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit … Ended recruitment
  2024-512243-23-00 5 2014-11-07 gastrointestinal stromal tumor
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke Halted
  2023-506178-11-00 5 2025-11-11 Acute ischemic stroke
• CAPSI - Cancer related major depression treated with a single dose of psilocybin - a multicenter randomized placebo controlled double blind … Halted
  2023-505532-35-00 4 2024-05-15 Malignant tumours ICD 10 C00 to C97
• A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine … Halted
  2023-505829-14-00 5 2023-12-22 First recurrence glioblastoma
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole Compared to Letrozole Alone in Postmenopausal Wom … Ended
  2024-512848-30-00 4 2024-11-12 HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
• A multi-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of all … Ended
  2024-518757-42-00 9 2024-10-28 Difficult-to-heal venous leg ulcers
• A Phase I Study Using Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients with Melanoma and Liver Metastases Ended
  2024-512877-28-00 3 2024-10-23 Metastases to liver
• A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma Ended
  2024-516969-36-00 9 2024-09-16 Multiple Myeloma
• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• Phase 2 study comparing SAR447537 to plasma-derived A1PI therapy for AATD emphysema Ended
  2023-508084-76-00 4 2024-05-31 Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
• A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap … Ended
  2022-502653-34-01 11 2024-05-30 Atopic dermatitis and moderate-to severe atopic hand eczema
• BIOMarkers in Endometrial Cancer - A phase III open label randomized trial to determine the efficacy of biomarker staging as compared to con … Ended
  2023-505991-31-00 5 2024-04-30 ENDOMETRIAL CANCER
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 5 2024-03-08 Uncontrolled hypertension (uTHN) defined as blood pressure that remain
• A Window-of-Opportunity study of hormone therapy in premenopausal women with ER-positive/HER2-negative early breast cancer. Ended
  2022-503013-32-00 4 2024-01-29 ER-positive/HER2-negative early breast cancer
• A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended
  2022-502529-17-00 5 2024-01-18 Obesity
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder Ended
  2022-502077-42-00 10 2023-09-14 generalised anxiety disorder

Showing 241–264 of 303 trials